气道上皮细胞在哮喘发病机制中的作用研究进展

doi:10.3969/j.issn.1674-8115.2023.05.013

上海交通大学学报（医学版） ›› 2023, Vol. 43 ›› Issue (5): 619-623.doi: 10.3969/j.issn.1674-8115.2023.05.013

• 综述 • 上一篇

气道上皮细胞在哮喘发病机制中的作用研究进展

徐瀛濂(), 田静, 张翔, 赵顺英()

国家儿童医学中心，首都医科大学附属北京儿童医院呼吸二科，北京 100045

收稿日期:2022-12-12 接受日期:2023-03-17 出版日期:2023-05-28 发布日期:2023-07-11
通讯作者: 赵顺英 E-mail:kl09210622@163.com;Zhaoshunying2001@163.com
作者简介:徐瀛濂（1997—），女，硕士生；电子信箱：kl09210622@163.com。
基金资助:
国家自然科学基金(81370124)

Research progress in the roles of airway epithelial cells in the pathogenesis of asthma

XU Yinglian(), TIAN Jing, ZHANG Xiang, ZHAO Shunying()

National Center for Children′s Health, China; Department No. 2 of Respiratory Medicine, Beijing Children′s Hospital, Capital Medical University, Beijing 100045, China

Received:2022-12-12 Accepted:2023-03-17 Online:2023-05-28 Published:2023-07-11
Contact: ZHAO Shunying E-mail:kl09210622@163.com;Zhaoshunying2001@163.com
Supported by:
National Natural Science Foundation of China(81370124)

摘要/Abstract

摘要：

哮喘是一种常见的慢性呼吸道疾病。作为一种异质性疾病，其发病机制由免疫、遗传、环境等多种因素共同驱动，由多种细胞共同参与。近些年越来越多的证据表明，气道上皮细胞在哮喘发病中发挥核心作用。气道上皮细胞作为机体呼吸系统抵御外界环境的第一道防线，主要通过细胞间各种连接阻止有害刺激进入，并通过黏液纤毛系统和抗菌肽清除变应原、病毒等外来有害因素。气道黏膜受到外来有害刺激时，气道上皮细胞屏障可能被破坏，上皮细胞释放各种上皮源性细胞因子，有效激活树突状细胞（dendritic cell，DC）和Ⅱ型固有免疫淋巴细胞（type Ⅱ innate lymphoid cell，ILC），从而引发后续辅助性T细胞2免疫级联反应，导致哮喘发生。鉴于气道上皮细胞在哮喘中的上述作用，针对气道上皮细胞来源的细胞因子，如胸腺基质淋巴细胞生成素（thymic stromal lymphopoietin，TSLP）等的靶向治疗药物也逐渐投入临床应用。该文针对气道上皮细胞在哮喘发病机制中的作用，及以气道上皮细胞为潜在靶点的治疗在未来的临床应用进行综述。

关键词: 哮喘, 气道上皮细胞, 细胞因子, 靶向治疗

Abstract:

Asthma is a common chronic respiratory disease, and as a heterogeneous disease, it is driven by a combination of immune, genetic, and environmental factors and involves multiple cells. In recent years, there has been increasing evidence that airway epithelial cells play a core role in the pathogenesis of asthma. As the first line of defense of the respiratory system against the external environment, airway epithelial cells mainly prevent harmful stimuli from entering through various intercellular connections and remove harmful foreign factors such as allergens and viruses through the mucus and cilia system and the antimicrobial peptides. The airway epithelial barrier can be disrupted when the airway mucosa is exposed to foreign harmful stimuli, and epithelial cells can release various epithelial-derived cytokines that effectively activate dendritic cells and type Ⅱ innate lymphoid cells, thereby triggering a subsequent helper T cell 2 immune cascade response that leads to the development of asthma. In view of these roles of airway epithelial cells in asthma, targeted therapeutic agents targeting the cytokines from airway epithelial cells such as thymic stromal lymphopoietin, are gradually coming into clinical use. This article reviews the role of airway epithelial cells in the pathogenesis of asthma and the future clinical applications of therapies targeting airway epithelial cells as potential targets.

Key words: asthma, airway epithelium, cytokine, targeted therapy

中图分类号:

R562.2

徐瀛濂, 田静, 张翔, 赵顺英. 气道上皮细胞在哮喘发病机制中的作用研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(5): 619-623.

XU Yinglian, TIAN Jing, ZHANG Xiang, ZHAO Shunying. Research progress in the roles of airway epithelial cells in the pathogenesis of asthma[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(5): 619-623.

参考文献 38

1	REDDEL H K, BACHARIER L B, BATEMAN E D, et al. Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes[J]. Eur Respir J, 2022, 59(1): 2102730.
2	MILLER R L, GRAYSON M H, STROTHMAN K. Advances in asthma: new understandings of asthma′s natural history, risk factors, underlying mechanisms, and clinical management[J]. J Allergy Clin Immunol, 2021, 148(6): 1430-1441.
3	GOHY S, HUPIN C, LADJEMI M Z, et al. Key role of the epithelium in chronic upper airways diseases[J]. Clin Exp Allergy, 2020, 50(2): 135-146.
4	CALVÉN J, AX E, RÅDINGER M. The airway epithelium: a central player in asthma pathogenesis[J]. Int J Mol Sci, 2020, 21(23): E8907.
5	NOUREDDINE N, CHALUBINSKI M, WAWRZYNIAK P. The role of defective epithelial barriers in allergic lung disease and asthma development[J]. J Asthma Allergy, 2022, 15: 487-504.
6	HELLINGS P W, STEELANT B. Epithelial barriers in allergy and asthma[J]. J Allergy Clin Immunol, 2020, 145(6): 1499-1509.
7	LEGENDRE M, ZARAGOSI L E, MITCHISON H M. Motile cilia and airway disease[J]. Semin Cell Dev Biol, 2021, 110: 19-33.
8	GHEZZI M, POZZI E, ABBATTISTA L, et al. Barrier impairment and type 2 inflammation in allergic diseases: the pediatric perspective[J]. Children (Basel), 2021, 8(12): 1165.
9	MORETTA A, SCIEUZO C, PETRONE A M, et al. Antimicrobial peptides: a new hope in biomedical and pharmaceutical fields[J]. Front Cell Infect Microbiol, 2021, 11: 668632.
10	VON MUTIUS E, SMITS H H. Primary prevention of asthma: from risk and protective factors to targeted strategies for prevention[J]. Lancet, 2020, 396(10254): 854-866.
11	GON Y, HASHIMOTO S. Role of airway epithelial barrier dysfunction in pathogenesis of asthma[J]. Allergol Int, 2018, 67(1): 12-17.
12	LI B, ZOU Z, MENG F, et al. Dust mite-derived Der f 3 activates a pro-inflammatory program in airway epithelial cells via PAR-1 and PAR-2[J]. Mol Immunol, 2019, 109: 1-11.
13	REDES J L, BASU T, RAM-MOHAN S, et al. Aspergillus fumigatus-secreted alkaline protease 1 mediates airways hyperresponsiveness in severe asthma[J]. ImmunoHorizons, 2019, 3(8): 368-377.
14	GASPAR R, DE MATOS M R, CORTES L, et al. Pollen proteases play multiple roles in allergic disorders[J]. Int J Mol Sci, 2020, 21(10): 3578.
15	GODBOLD G D, KAPPELL A D, LESASSIER D S, et al. Categorizing sequences of concern by function to better assess mechanisms of microbial pathogenesis[J]. Infect Immun, 2022, 90(5): e0033421.
16	LOOI K, BUCKLEY A G, RIGBY P J, et al. Effects of human rhinovirus on epithelial barrier integrity and function in children with asthma[J]. Clin Exp Allergy, 2018, 48(5): 513-524.
17	MILLS J T, SCHWENZER A, MARSH E K, et al. Airway epithelial cells generate pro-inflammatory tenascin-C and small extracellular vesicles in response to TLR3 stimuli and Rhinovirus infection[J]. Front Immunol, 2019, 10: 1987.
18	BOULET L P. Airway remodeling in asthma: update on mechanisms and therapeutic approaches[J]. Curr Opin Pulm Med, 2018, 24(1): 56-62.
19	MIETHE S, GUARINO M, ALHAMDAN F, et al. Effects of obesity on asthma: immunometabolic links[J]. Pol Arch Intern Med, 2018, 128(7/8): 469-477.
20	MICHALIK M, WÓJCIK-PSZCZOŁA K, PAW M, et al. Fibroblast-to-myofibroblast transition in bronchial asthma[J]. Cell Mol Life Sci, 2018, 75(21): 3943-3961.
21	ROUT-PITT N, FARROW N, PARSONS D, et al. Epithelial mesenchymal transition (EMT): a universal process in lung diseases with implications for cystic fibrosis pathophysiology[J]. Respir Res, 2018, 19(1): 136.
22	ANDERSON E D, ALISHAHEDANI M E, MYLES I A. Epithelial-mesenchymal transition in atopy: a mini-review[J]. Front Allergy, 2020, 1: 628381.
23	YÜKSEL H, TUNCA S. Destiny of airway disease: interplay between epithelial barrier and the innate immune system[J]. Tissue Barriers, 2022, 10(4): 2020706.
24	DAVIS J D, WYPYCH T P. Cellular and functional heterogeneity of the airway epithelium[J]. Mucosal Immunol, 2021, 14(5): 978-990.
25	WHETSTONE C E, RANJBAR M, OMER H, et al. The role of airway epithelial cell alarmins in asthma[J]. Cells, 2022, 11(7): 1105.
26	KLIMOV V, CHEREVKO N, KLIMOV A, et al. Neuronal-immune cell units in allergic inflammation in the nose[J]. Int J Mol Sci, 2022, 23(13): 6938.
27	BOROWCZYK J, SHUTOVA M, BREMBILLA N C, et al. IL-25 (IL-17E) in epithelial immunology and pathophysiology[J]. J Allergy Clin Immunol, 2021, 148(1): 40-52.
28	DENG C, PENG N, TANG Y, et al. Roles of IL-25 in type 2 inflammation and autoimmune pathogenesis[J]. Front Immunol, 2021, 12: 691559.
29	WANG W, LI Y, LV Z, et al. Bronchial allergen challenge of patients with atopic asthma triggers an alarmin (IL-33, TSLP, and IL-25) response in the airways epithelium and submucosa[J]. J Immunol, 2018, 201(8): 2221-2231.
30	HARTUNG F, ESSER-VON BIEREN J. Trained immunity in type 2 immune responses[J]. Mucosal Immunol, 2022, 15(6): 1158-1169.
31	SAIKUMAR JAYALATHA A K, HESSE L, KETELAAR M E, et al. The central role of IL-33/IL-1RL1 pathway in asthma: from pathogenesis to intervention[J]. Pharmacol Ther, 2021, 225: 107847.
32	HUANG R F, MAO W, WANG G L, et al. Synergistic relationship between TSLP and IL-33/ST2 signaling pathways in allergic rhinitis and the effects of hypoxia[J]. Int Forum Allergy Rhinol, 2020, 10(4): 511-520.
33	YAO X J, LIU X F, WANG X D. Potential role of interleukin-25/interleukin-33/thymic stromal lymphopoietin-fibrocyte axis in the pathogenesis of allergic airway diseases[J]. Chin Med J (Engl), 2018, 131(16): 1983-1989.
34	AKAR-GHIBRIL N, CASALE T, CUSTOVIC A, et al. Allergic endotypes and phenotypes of asthma[J]. J Allergy Clin Immunol Pract, 2020, 8(2): 429-440.
35	MENZIES-GOW A, CORREN J, BOURDIN A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma[J]. N Engl J Med, 2021, 384(19): 1800-1809.
36	BACHARIER L B, JACKSON D J. Biologics in the treatment of asthma in children and adolescents[J]. J Allergy Clin Immunol, 2023, 151(3): 581-589.
37	WECHSLER M E, RUDDY M K, PAVORD I D, et al. Efficacy and safety of itepekimab in patients with moderate-to-severe asthma[J]. N Engl J Med, 2021, 385(18): 1656-1668.
38	AnaptysBio, Inc. Efficacy, safety, and pharmacokinetic profile of etokimab (ANB020) in adult participants with moderate-to-severe atopic dermatitis (ATLAS)[EB/OL]. [2022-11-20]. https://clinicaltrials.gov/ct2/show/NCT03533751.

[1]	梅艳青, 韩雨洁, 翁文筠, 张蕾, 唐玉杰. 靶向抑制CDK12/13在高级别胶质瘤中的体外治疗效果和作用分子机制探究[J]. 上海交通大学学报（医学版）, 2023, 43(5): 545-559.
[2]	胡煜, 谢亮, 邹丹, 伏洪玲, 娄丽丽, 谢柯祺, 刘瀚旻. 孟鲁司特对哮喘中白三烯B4代谢的影响[J]. 上海交通大学学报（医学版）, 2023, 43(5): 580-591.
[3]	谢欣宜, 周薇, 邱澈, 沈慧, 宋忠臣. 伴阿尔茨海默病牙周炎患者血清Th17/Treg相关细胞因子水平变化研究[J]. 上海交通大学学报（医学版）, 2023, 43(5): 600-605.
[4]	朱思宇, 董晓艳. 哮喘儿童小气道功能障碍的再认识[J]. 上海交通大学学报（医学版）, 2023, 43(4): 500-506.
[5]	刘铁鑫, 林俊卿, 郑宪友. 靶向亚细胞结构治疗脊髓损伤的研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(2): 230-236.
[6]	邓云天, 熊文魁, 朱芮, 刘恩梅, 李雪梅, 钟朝晖. 生命早期环境因素暴露与儿童哮喘关系的病例对照研究[J]. 上海交通大学学报（医学版）, 2023, 43(1): 44-51.
[7]	韩永琪, 韩达, 閤谦, 姬丁坤, 谭蔚泓. 核酸适体药物偶联物——肿瘤精准治疗新风向[J]. 上海交通大学学报（医学版）, 2022, 42(9): 1176-1181.
[8]	卫晓薇, 田福举, 刘晓瑞, 曾维宏, 陈彩莲, 林羿. 敲减TCF3抑制人子宫内膜基质细胞蜕膜化的研究[J]. 上海交通大学学报（医学版）, 2022, 42(9): 1247-1257.
[9]	李昕雨, 左斌, 王文, 钮晓音, 翁震, 何杨. 脂联素在免疫性血小板减少症患者外周血中的水平及其对巨核细胞系分化的作用[J]. 上海交通大学学报（医学版）, 2022, 42(7): 866-874.
[10]	雷海桃, 田雪梅, 金芳全. 细胞因子信号转导抑制因子与类风湿关节炎的相关性研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(7): 945-951.
[11]	康文慧, 陈仪婷, 赵安达, 李荣, 李生慧. 褪黑素在哮喘发病和病程中的作用机制研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(5): 667-672.
[12]	陈仪婷, 赵安达, 李荣, 康文慧, 李生慧. 循环外泌体微RNA在支气管哮喘中的作用综述[J]. 上海交通大学学报（医学版）, 2022, 42(3): 375-380.
[13]	李若楠, 陈小科, 许元元, 谭强. ⅠB~ⅢA期非小细胞肺癌患者术后辅助靶向治疗研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(11): 1612-1619.
[14]	董玉山, 张文杰. 细胞因子治疗骨关节炎的研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(11): 1627-1632.
[15]	陈锐, 赵云, 赵晓霞, 马东, 韩一江, 赖登明, 顾伟忠, 钭金法. 沉默信息调节因子1在新生儿坏死性小肠结肠炎肠组织中的表达特点[J]. 上海交通大学学报(医学版), 2021, 41(9): 1154-1161.

气道上皮细胞在哮喘发病机制中的作用研究进展

Research progress in the roles of airway epithelial cells in the pathogenesis of asthma

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 38

相关文章 15

编辑推荐

Metrics